

THE POWER OF MORE

More for your science, from start to finish.

Precision medicine demands more from every program: assays are intricate, the regulatory bar is high, and results must be reproducible across platforms, sites, and phases. To get it right, you need a CRO partner that rises to the challenge, no matter the program size or scientific demand.

CellCarta is a global precision medicine CRO that brings genomics, histopathology, immunology, and proteomics together. From discovery to phase III trials and CDx, you get the scientific depth, operational scale, and hands-on partnership your program deserves. Our fit-for-purpose assay development adapts with your program as it evolves, delivering regulatory-ready data with standardized global workflows that keep your data consistent across clinical sites and development phases.



25+ years of advanced biomarker expertise and bioanalytical testing solutions



Rapid development of complex assays for clinical studies



Bioinformatics team for data interpretation



Customizable bioanalytical workflows and platform selection



Deep scientific knowledge with >750 employees, including PhDs and MDs



ML/AI algorithms and digital pathology



Worldwide sample logistic solutions and clinical trial support



CAP, CLIA, and ISO accredited facilities operating under a globally harmonized QMS



Expertise in IVD, CDx, and global regulatory requirements, including IVDR and HGRAC

MORE WAYS TO MOVE YOUR PROGRAM FORWARD.

Our broad portfolio of biomarker modalities delivers all the services you need for your clinical trials - from translational research, through clinical development, and CDx.



Immune monitoring

Characterize immune response with technologies such as flow and mass cytometry, and key functional assays like ELISpot and ICS, using pre-validated or custom panels.

- Flow Cytometry (Spectral and Conventional)
- Mass Cytometry (CyTOF)



Genomics

Profile mutations and expression with NGS, qPCR/dPCR, RNAseq, and WES, and monitor disease using solid tumor or liquid biopsy samples, including circulating tumor cell monitoring.

- NGS
- Quantitative PCR
- WES
- RNAseq
- Single-cell Sequencing
- WGS
- Digital PCR
- Spatial Transcriptomic



Proteomics

Quantify protein biomarkers with multiplexed MRM and PRM mass spectrometry and validated immunoassays, including Olink (certified service provider), MSD, ELLA, and ELISA.

- Immunoassays (Olink, MSD, ELLA)
- Mass Spectrometry



Histopathology

Turn tissue into data with custom IHC, multiplex IHC, ISH, and spatial biology platforms, interpreted by our 20+ in-house pathologists and AI-powered digital analysis.

- IHC/IF (Multiplex)
- Spatial Biology
- ISH
- Pathology & Digital Pathology



Companion diagnostics (CDx)

Develop and validate a companion diagnostic with in-house assay expertise and regulatory submission support (FDA, IVDR, IVDD and HGRAC), built on the same platforms that run your clinical program.



Sample management & logistics

Keep samples trial-ready with global kitting, PBMC processing, and actively monitored biorepositories, with quality controls delivering >95% recovery rates across every clinical site.

- Kitting and Lab Manuals
- Sample Logistics
- Biorepository Services



Data, bioinformatics & biostatistics

Make sense of complex, multi-modal data with in-house bioinformaticians and biostatisticians, and our proprietary analysis and visualization tools, including CellEngine.

OUR PROCESS

FROM FIRST SAMPLE TO FINAL INSIGHT.

We manage the entire workflow end-to-end, from receiving and tracking your samples to interpreting the final data. Each stage connects to the next, ensuring your program operates seamlessly and your data stays consistent from start to finish.



**Sample Management
& Logistics**



**Collaborative
Assay Design**



**Timely Clinical
Testing**



**AI-Driven Data
Generation**



**Biological
Interpretation**

MORE CONFIDENCE IN EVERY RESULT.

Our in-house biobank: Samples ready when you are.

Skip sourcing delays and get immediate access to 5,000+ fully consented samples, searchable by phenotype, biomaterial, and indication. Move straight into genomics, proteomic, imaging, and liquid biopsy assays from matched tissue and liquid samples, shaving 4-6 weeks off your timeline.

Built for complex programs.

When a modality is novel – an ADC, a TPD, a cell therapy – proving how it works, and in which patients, takes more than off-the-shelf assays. Across oncology, immunology, neurology, and infectious disease, our PhD scientists will plan and build a custom biomarker strategy with you.

Move fast on CDx, commit fully only once it's proven.

Our hybrid centralized/decentralized CDx Accelerator model validates a PMA assay in 1.5-2 years, so your companion diagnostic is ready the day your therapy is approved, limiting upfront cost on an IVD build until clinical success is clear. From there, we manage the handoff to a lab network to scale globally.

Quality is integrated into everything we do. Our CAP-accredited, CLIA-certified labs operate under GCLP and ISO 13485, 15189, and 27001 frameworks.

A risk-based quality management system governs every stage of work – nonclinical, clinical, and IVD. That rigor is tested constantly: we host sponsor audits and routinely clear FDA BIMO and regulatory inspections, with no critical findings.

A GLOBAL PRESENCE WITH LOCAL EXPERTISE.


Since our globally owned labs operate as a single integrated network, samples move with less workflow friction and remain on a single chain of custody. Cross-validated instrumentation, standardized processes, and a harmonized QMS, extend that consistency across North America, Europe, Australia and China, and into broader global clinical trial reach. Together, this means you get more value from every sample and reach enrollment-ready decisions faster.

CellCarta in China

Extend your program into one of the world's fastest-growing trial markets, without the added complexity. Our fully owned, CAP-accredited lab in Jining runs the same modalities, SOPs, and quality systems as our labs across North America, Europe, and Australia, so expanding into China feels less like a leap and more like a natural next step.



Discover what the power of more can do for you.



About CellCarta

CellCarta is a global CRO supporting biopharma with reliable, regulatory-ready biomarker data from translational research to CDx. Through owned, harmonized labs in North America, Europe, Australia and China, CellCarta delivers integrated capabilities spanning immunology, histopathology, proteomics, and genomics, supported by comprehensive sample management and logistics.

www.cellcarta.com

